Liu Jia, Fu Jing, Duan Yan, Wang Guang
Department of Endocrinology; Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Front Endocrinol (Lausanne). 2017 Sep 29;8:258. doi: 10.3389/fendo.2017.00258. eCollection 2017.
Graves' disease (GD) is one of the most common endocrine diseases. Antithyroid drugs (ATDs) treatment is frequently used as the first-choice therapy for GD patients in most countries due to the superiority in safety and tolerance. However, GD patients treated with ATD have a relatively high recurrence rate after drug withdrawal, which is a main limitation for ATD treatment. It is of great importance to identify some predictors of the higher recurrence risk for GD patients, which may facilitate an appropriate therapeutic approach for a given patient at the time of GD diagnosis. The genetic factor was widely believed to be an important pathogenesis for GD. Increasing studies were conducted to investigate the relationship between gene polymorphisms and the recurrence risk in GD patients. In this article, we updated the current literatures to highlight the predictive value of gene polymorphisms on recurrence risk in GD patients after ATD withdrawal. Some gene polymorphisms, such as rs231775, human leukocyte antigen polymorphisms (, and ) might be associated with the high recurrence risk in GD patients. Further prospective studies on patients of different ethnicities, especially studies with large sample sizes, and long-term follow-up, should be conducted to confirm the predictive roles of gene polymorphism.
格雷夫斯病（GD）是最常见的内分泌疾病之一。在大多数国家，抗甲状腺药物（ATD）治疗因其安全性和耐受性方面的优势，常被用作GD患者的首选治疗方法。然而，接受ATD治疗的GD患者停药后复发率相对较高，这是ATD治疗的一个主要局限性。识别一些GD患者复发风险较高的预测因素非常重要，这可能有助于在GD诊断时为特定患者制定合适的治疗方案。遗传因素被广泛认为是GD的重要发病机制。越来越多的研究致力于探讨基因多态性与GD患者复发风险之间的关系。在本文中，我们更新了当前文献，以突出基因多态性对GD患者停用ATD后复发风险的预测价值。一些基因多态性，如rs231775、人类白细胞抗原多态性（ 、 和 ）可能与GD患者的高复发风险相关。应针对不同种族的患者开展进一步的前瞻性研究，尤其是大样本量、长期随访的研究，以证实基因多态性的预测作用。
